Takeda to buy back more shares
This article was originally published in Scrip
Executive Summary
The board of Takedahas approved the purchase of up to a further nine million of the company's own shares for a maximum of ¥50 billion ($472.6 million). The programme adds to the ¥100 billion worth of shares, around 2% of the Japanese firm's issued total, which were acquired earlier this year and cancelled in June. Takeda and several other Japanese pharma majors have been implementing buybacks to improve shareholder returns and guard against possible hostile takeovers.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Asia Deal Watch: LianBio Partners With Pfizer In Greater China, Gets Financial Backing
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Need a specific report? 1000+ reports available
Buy Reports